The pharmacodiagnostic tests are intended to identify the patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb.
Dakos CEO Lars Holmkvist said the partnership agreements simply underpin the company’s mission to deliver the highest standards and accurate diagnoses — ultimately to the benefit of patients.